Novocure Q3 2026 Earnings - NOVOCURE LTD

Explicit Guidance:

• Revenue: Updated 2026 net revenue guidance raised to $736–$743 million, representing 12–13% year-over-year growth. This range includes $30–$34 million collectively from Optum Lua and Optune Pax.
• Adjusted EBITDA: Full-year 2026 adjusted EBITDA guidance updated to a range of $24–$34 million (vs. previous $2–$12 million implied range). Management targets cash flow breakeven in 2027 as the next milestone.
• Margins: Gross margin expected to remain in the mid-to-high 70s (specifically maintaining Q3's 77% level) through the final quarter of 2026.
• Expenses: R&D costs projected to stay roughly flat or decline in the foreseeable future, as large Phase 3 trials (Keynote D58, Luna 2) roll off. G&A expenses targeted to remain flat with minimal increases due to inflation. Sales and marketing expenses expected to leverage existing forces with limited incremental investments for 2027 launches.
• Non-GAAP: No forward-looking guidance provided for GAAP net income or share-based compensation.

Business-Segment Outlook:

• OptumGEO (GBM): Active patient count reached a record 4,729 (11% YoY growth). Management expects continued momentum and increased adoption in existing and new markets. Keynote D58 trial (combining OptumGEO, pembrolizumab, and low-dose chemo) is on track to complete enrollment by year-end 2026.
• Optum Maya (Brain Metastases from NSCLC): PMA application under FDA review; a final decision is expected by year-end 2026, with a commercial launch targeted for early 2027. Reimbursement expected within two years of launch.
• Optum Pax (Pancreatic Cancer): Launching in the U.S. faced headwinds due to the entry of Deraxon Racib and practice capacity constraints, but management expects growth to return in coming quarters. Two new trials (Penova 5 and Penova 6) exploring concomitant use with KRAS inhibitors (VS-7375) and Deraxon Racib are planned for initiation in the first half of 2027. NCCN guideline updates for pancreatic cancer are anticipated end of 2026 or early 2027.
• Optum Lua (Lung Cancer in Japan): Strong momentum with 255 global active patients and $8M quarterly revenue (Japan contribution: 110 patients, $4M). Reimbursement for Optum Pax in Japan is expected in the first half of 2027, which would enable the Pax launch there. Japan is projected to become the company's second-largest market behind the U.S.

Market and Competitive Outlook:

• U.S. Pancreatic Market: Significant short-term headwind due to the launch of Deraxon Racib (KRAS inhibitor), causing practice overwhelm regarding insurance appeals and skin irritation management. Management anticipates this "practice disruption" to settle in the coming quarters, allowing renewed focus on Optune Pax.
• Competitive Strategy: Acknowledges Deraxon Racib's approval does not yet signal widespread first-line adoption except in chemo-intolerant patients. Focus remains on establishing Optune Pax as standard of care via clinical trials and NCCN guideline inclusion.
• Pricing: Negotiated price for Optum Lua in Japan is approximately aligned with global OptumGEO pricing. Optum Pax pricing in Japan has been reset to levels potentially higher than OptumGEO's.

Macro / Industry Outlook:

• Japan Market Dynamics: Highlighted as a major structural tailwind; pancreatic cancer incidence in Japan is higher than in the U.S., and lung cancer incidence is significant.
• Standard of Care Evolution: Expectation of a "wave of recurrence" later in 2026 from KRAS inhibitor therapies, creating a future demand sweet spot for TTF therapy in recurrent settings.
• Regulatory: Pending FDA decision on Optum Maya by year-end 2026; NCCN guideline update for pancreatic cancer expected end of 2026 or early 2027.

Strategic Initiatives:

• Clinical Trials:
  • Penova 5: Initiation expected H1 2027; investigates Optum Pax + gemcitabine + nab-paclitaxel + VS-7375 in locally advanced PDAC.
  • Penova 6: Initiation expected H1 2027; investigates Optum Pax + Deraxon Racib in metastatic PDAC.
• Partnerships: Collaboration with VeriSTEM (KRAS inhibitor partner) for Penova 5.
• Operational Efficiency: Structural changes implemented to accelerate transition to profitability; supply chain optimization continuing to support larger patient populations.
• 2027 Goals: Commitment to double-digit top-line growth in 2027 driven by OptumGEO expansion, Optum Lua momentum, and Optum Pax recovery.

Risks and Headwinds to Outlook:

• Practice Overload: Current U.S. sales velocity for Optum Pax is limited by physician capacity to manage insurance appeals and skin irritation for the competing Deraxon Racib therapy.
• Seasonality: Q4 is historically difficult to estimate due to preparation for next year's launches; management warns against expecting a straight-line sequential increase in adjusted EBITDA.
• Trial Uncertainty: Penova 5 and 6 are small, single-arm safety/feasibility trials; results may not prove synergistic clinical benefit or tolerability.
• One-time Items: Q3 revenue included a one-time $4M benefit from approval rate increases; revenue guidance accounts for this volatility.

Management Tone on the Future:

• Confidence: Highly confident in the path to profitability, having achieved positive adjusted EBITDA ($16M) for the quarter and record revenue ($193M).
• Strategic Shift: Explicit transition from "growth at all costs" to "profitability and cash flow," with two of three profitability steps (adjusted EBITDA breakeven) now achieved.
• Commitment: Reiterated dedication to the Optum Pax indication despite short-term friction, viewing the market disruption as temporary and solvable via continued evidence generation.
• Hedges: Avoided specific 2027 revenue targets, focusing instead on the 2026 guidance and the general aspiration for double-digit growth in 2027.

Miscellaneous:

• Cash Position: Cash and investments as of September 30, 2026, stood at $463 million.
• Share-Based Compensation: Lower SBC expenses drove significant reductions in G&A and sales/marketing costs; expected to remain a key lever for margin expansion.
• Patient Experience: Active patient count growth is driven by both new and established markets, with a focus on optimizing outreach timing in the treatment journey.